DefEYE, Inc. Announces Investment from ExSight Ventures
Investment Supports Commercialization of Innovative Decellularized Placental Tissue Technology for Ocular Surface Disease and Surgical Management NEW YORK–(BUSINESS WIRE)–ExSight Ventures, a leading venture capital firm focused on transformational eye care innovations, today announced its investment in DefEYE, Inc., a rapidly growing ocular company developing decellularized placental-based tissue solutions to transform and personalize therapeutic approaches in […]
Sydnexis Announces UK Approval of Ryjunea® by Partner Santen to Slow Progression of Childhood Myopia
DEL MAR, Calif.–(BUSINESS WIRE)–Sydnexis, Inc., a biopharmaceutical company focused on pediatric progressive myopia (PPM), today noted its partner Santen’s announcement that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea® (low-dose atropine 0.1 mg/ml), the first MHRA approved treatment in the UK to slow the progression of myopia in children aged 3-14 years […]